Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Scinai Immunotherapeutics Ltd. (SCNI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
3Distinct source URLs
10High confidence
0.843Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Scinai Immunotherapeutics Ltd. Suppliers
Ticker
Name
Confidence
Evidence
RECIPHARM-ISRAEL-LTD
RECIPHARM-ISRAEL-LTD
92%
On February 17, 2026, we acquired 100% of the shares of Recipharm Israel Ltd., which operates a manufacturing site in Yavne, Israel, and entered into a long-term strategic commercial collaboration wi…
Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we…
Reciprocal relationship from MLTX graph: Reciprocal relationship from SCNI graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from SCNI graph: Reciprocal relationship from MLTX g…
SNYNF
Sanofi
72%
e Israeli Ministry of Environmental Protection in order to verify compliance with relevant instructions and regulations. In addition, all of our laboratory personnel participate in instruction on the…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SCNI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SCNI graph: e Israeli Ministry of Environment…
RECIPHARM-ISRAEL-LTD
RECIPHARM-ISRAEL-LTD
62%
significant unmet medical need. 40 CDMO Services On September 6, 2023, we announced the launch of a new business unit, Scinai Bioservices (now renamed Scinai Biopharma Services), focused on providing…
STRATEGIC-COMMERCIAL-CO
STRATEGIC-COMMERCIAL-CO
62%
nd small-molecule programs. This expanded platform is intended to support a wider range of customer needs and increase our ability to attract and retain clients. Strategic Commercial Collaboration wi…
Scinai Immunotherapeutics Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
SCNI-DEBT
Debt stack $382,000
90%
Market cache reports total debt of $382,000.
SCNI-DEBT-12421
Warrants outstanding: 1638062
90%
xbrl warrant detail from xbrl 2025-07-31.
Scinai Immunotherapeutics Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Scinai Immunotherapeutics Ltd..
Scinai Immunotherapeutics Ltd. Ownership
Holder
Name
Confidence
Evidence
SCNI-OWNER-RHUMBLINE-ADVISERS
Rhumbline Advisers
95%
13F/ownership overlay lists Rhumbline Advisers; shares held 1,878; ownership 0.05%; value $1,384; as of 2025-12-31.
SCNI-OWNER-MORGAN-STANLEY
Morgan Stanley
95%
13F/ownership overlay lists Morgan Stanley; shares held 58; value $42; as of 2025-12-31.
SCNI-OWNER-VIRTU-FINANCIAL-LLC
Virtu Financial LLC
95%
13F/ownership overlay lists Virtu Financial LLC; shares held 15,409; ownership 0.44%; value $11,356; as of 2025-12-31.
SCNI-OWNER-UBS-GROUP-AG
UBS Group AG
95%
13F/ownership overlay lists UBS Group AG; shares held 1,748; ownership 0.05%; value $1,288; as of 2025-12-31.
SCNI-OWNER-XTX-TOPCO-LTD
Xtx Topco Ltd
95%
13F/ownership overlay lists Xtx Topco Ltd; shares held 27,294; ownership 0.77%; value $20,115; as of 2025-12-31.
